U.S., Aug. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07754045) titled 'Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults' on July 09.
Brief Summary: This is a phase 2 randomized, double-blind, placebo-controlled, multi-center study evaluating the efficacy and safety of LUM-201 plus Semaglutide versus Semaglutide plus placebo in obese adults with body mass index between 30 and 45 kg/m^2, between the ages of 60 and 85 years that have mild functional impairment.
Study Start Date: Feb. 15, 2027
Study Type: INTERVENTIONAL
Condition:
Obesity & Overweight
Intervention:
DRUG: LUM-201
Daily (AM) oral Tablet at 25 mg
DRUG: Placebo
Daily ...